StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research note on Monday, September 23rd. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Up 41.7 %

NASDAQ MRNS opened at $0.53 on Friday. Marinus Pharmaceuticals has a 1-year low of $0.22 and a 1-year high of $11.26. The firm’s fifty day simple moving average is $0.37 and its 200-day simple moving average is $1.07. The company has a market capitalization of $29.03 million, a PE ratio of -0.21 and a beta of 1.25.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC acquired a new position in shares of Marinus Pharmaceuticals during the second quarter worth approximately $727,000. Acadian Asset Management LLC bought a new position in Marinus Pharmaceuticals during the second quarter worth $813,000. Hussman Strategic Advisors Inc. raised its stake in Marinus Pharmaceuticals by 14.3% during the 2nd quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 10,500 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $206,000. Finally, AQR Capital Management LLC grew its position in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.